Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination

Core Viewpoint - Scilex Holding Company announced the successful closing of a business combination with Denali Capital Acquisition Corp, resulting in the formation of Semnur Pharmaceuticals, Inc., which will focus on non-opioid pain management products [1][2][3] Company Overview - Scilex is dedicated to acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain, as well as neurodegenerative and cardiometabolic diseases [1][5] - The company aims to address high unmet needs in the market with its innovative therapies [5] Business Combination Details - The combined entity will operate under the name Semnur Pharmaceuticals, Inc., with shares trading on the OTC Markets under the ticker symbols "SMNR" and "SMNRW" [2][6] - Scilex holds approximately 87.5% of Semnur's common stock post-business combination [6] Leadership Statements - Henry Ji, CEO of Scilex, emphasized the importance of public capital markets for business growth and fulfilling the mission of addressing non-opioid pain management needs [3] - Jaisim Shah, CEO of Semnur, expressed pride in leading the development of prescription non-opioid therapeutics and aims to accelerate access to these treatments [3] Product Pipeline - Semnur's lead product candidate, SP-102 (SEMDEXA), is a novel gel formulation for epidural administration targeting chronic radicular pain/sciatica [10] - Scilex has additional product candidates, including SP-103 and SP-104, targeting acute pain and fibromyalgia, respectively [8]